3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Colorectal Neoplasms
8
Venous Thromboembolism
4
Polycythemia Vera
3
Prostatic Neoplasms
2
Neoplasms
2
Myeloproliferative Disorders
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms, Hereditary Nonpolyposis
2
Breast Neoplasms
2
Thrombocythemia, Essential
1
Testicular Neoplasms
1
Smoking Cessation
1
Sarcoma
1
Primary Myelofibrosis
1
Ovarian Neoplasms
1
Ovarian Cancer Prevention
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms, Germ Cell and Embryonal
1
Multiple Myeloma
1
Motor Activity
1
Lung Neoplasms
1
Liver Cirrhosis
1
Leukemia, Hairy Cell
1
Inflammation
1
Hemorrhage
1
Hematoma
1
Fibrosis
1
Endometrial Neoplasms
1
Colorectal Neoplasia
1
Interventions
Etoposide
7
Cisplatin
7
fludarabine
4
Cyclophosphamide
4
fludarabine phosphate
3
Paclitaxel
3
Carboplatin
3
Bleomycin
3
Automobiles
3
pembrolizumab
2
etoposide phosphate
2
Vorinostat
2
Sirolimus
2
Mesna
2
Ifosfamide
2
Drug Therapy
2
130-nm albumin-bound paclitaxel
2
tremelimumab
1
sodium thiosulfate
1
repotrectinib
1
pralsetinib
1
pegfilgrastim
1
lutetium Lu 177 dotatate
1
durvalumab
1
cabozantinib
1
Watchful Waiting
1
Teniposide
1
Surveys and Questionnaires
1
Stem Cell Transplantation
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Germ Cell and Embryonal
×
Aspirin
×
1 year
×
Clear all
NCT06866964
2026-02-02
ASPIRE
Wake Forest University Health Sciences
Phase 2
Recruiting
35 enrolled